MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1055/a-0966-9915

Медицинская библиотека · Zeitschrift fur Geburtshilfe und Neonatologie · 2019

[Therapy Options for Infants with Congenital Cytomegalovirus Infection - Implications for Setting Up Neonatal Screening Programs].

Bührer Christoph, Blankenstein Oliver, Rossi Rainer, für die Screeningkommission der Deutschen Gesellschaft für Kinder- und Jugendmedizin (Mitglieder am Ende des Artikels)

СтатьяСистематический обзорПеревод в очереди

Аннотация

INTRODUCTION

The number of diseases covered by universal neonatal screening in Germany has risen steadily from 1 (phenylketonuria) in 1968 to 17 (with hearing impairment and congenital hip dysplasia) in 2018. Treatment, however, of disorders diagnosed by screening may harm children, as failed neuroblastoma screening has shown. There are several pilot studies to detect congenital cytomegalovirus (CMV) infection but no consensus as to the treatment of the infants identified.

METHODOLOGY: Systematic search for studies investigating therapy of congenital CMV infection, using PubMed and the WHO International Clinical Trials Registry Platform (ICTRP).

RESULTS

We found only one controlled trial that randomized infants with symptomatic congenital CMV infection (involving the central nervous system) to treatment (intravenous ganciclovir for 6 weeks) or no treatment. Treatment was associated with significantly less hearing deterioration. A second trial comparing 6 weeks vs. 6 months of treatment with valganciclovir, an oral prodrug of ganciclovir, found no benefit for hearing but modestly improved developmental outcomes associated with 6 months of treatment. In contrast, an open-label registry reported benefits for infants with congenital CMV infection and isolated hearing who received valganciclovir for 12 months, with hearing improvement in 2/3 of cases after a median follow-up of 4½ years.

CONCLUSIONS

Antiviral treatment of neonates with congenital CMV infection and few symptoms including isolated hearing loss remains controversial. A generally accepted therapy, however, is pivotal before introducing universal or targeted screening for congenital CMV infection.

Для цитирования: Bührer Christoph, Blankenstein Oliver, Rossi Rainer, für die Screeningkommission der Deutschen Gesellschaft für Kinder- und Jugendmedizin (Mitglieder am Ende des Artikels). [Therapy Options for Infants with Congenital Cytomegalovirus Infection - Implications for Setting Up Neonatal Screening Programs].. Zeitschrift fur Geburtshilfe und Neonatologie. 2019. DOI: 10.1055/a-0966-9915.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.